

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/668,988
				Confirmation Number	1777
				Filing Date	September 22, 2003
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1618
Examiner Name	Young, M.P.				
Attorney Docket No.	50450-8060				
Sheet	1	of			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	US-5,288,711		Mitchell et al.	02-22-1994	
	2.	US-5,516,781		Morris et al.	05-14-1996	
	3.	US-5,756,673		Somenshein et al.	05-26-1998	
	4.	US-6,273,913		Wright et al.	08-14-2001	
	5.	US-6,369,039		Palasis et al.	04-09-2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent or Application			Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)			
	6.	PCT	WO98/00172		The Board of Regents of the University of Nebraska	01-08-1998	
	7.	PCT	WO00/02588	A1	The Board of Regents of the University of Nebraska	01-20-2000	
	8.	PCT	WO00/44897	A1	AVI Biopharma, Inc.	08-03-2000	

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T
	9.	BADIMON et al., "Cell Biology of Restenosis Post Angioplasty", <i>Zeitschrift fur Kardilogie</i> , <u>84</u> (Suppl 4)45-49 (Abstract only) (1995).		
	10.	Basso et al., "Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice", <i>Transplant Proc.</i> , <u>35</u> (8):3136-8 (2003).		
	11.	BAUTERS et al., "Proto-oncogene expression in rabbit aorta after wall injury. First marker of the cellular process leading to restenosis after angioplasty?", <i>European Heart Journal</i> , <u>13</u> (4):556-559 (1992).		
	12.	BENNETT et al., "Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides", <i>Journal of Clinical Investigation</i> , <u>93</u> (2):820-828 (1994).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/668,988
				Confirmation Number	1777
				Filing Date	September 22, 2003
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1618
Examiner Name	Young, M.P.				
Attorney Docket No.	50450-8060				
Sheet	2	of	4		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	13.	BENNETT, M.R. and O'SULLIVAN, M., "Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy", <i>Pharmacology &amp; Therapeutics</i> , <u>91</u> :149-166 (2001).	
	14.	Copy of the International Search Report for PCT/US03/13892, dated September 16, 2003, 2 pages (2003).	
	15.	Copy of the International Preliminary Examination Report for PCT/US03/13892, dated May 3 2005, 3 pages (2005).	
	16.	CHONG, P.H. and CHENG, J.W.M., "Early experiences and clinical implications of drug-eluting stents: part 1", <i>Ann Pharmacother.</i> , <u>38</u> (4):661-9 (2004).	
	17.	ELLOSO et al., "Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice", <i>American Journal of Transplantation</i> , <u>3</u> :562-569 (2003).	
	18.	FORTE et al., "Molecular analysis of arterial stenosis in rat carotids", <i>J Cell Physiol.</i> , <u>186</u> (2):307-13 (2001).	
	19.	GALLO et al., "Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle", <i>Circulation</i> , <u>99</u> :2164-2170 (1999).	
	20.	GREGORY et al., "Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels", <i>Transplantation</i> , <u>55</u> (6):1409-18 (1993).	
	21.	HISER et al., "Non-Invasive Inhibition of Carotid Artery Neointimal Formation and Vascular Remodeling Following Balloon Injury by Treatment with Intravenous Antisense to the c-myc Protooncogene Bound to Perfluorocarbon Microbubbles," <i>Circulation</i> , <u>98</u> (17 Suppl.):I191-292 (1998).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/668,988
				Confirmation Number	1777
				Filing Date	September 22, 2003
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1618
Examiner Name	Young, M.P.				
Sheet	3	of	4	Attorney Docket No.	50450-8060

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	22.	JANIKOWSKI et al., "Albumin Microbubbles Preferentially Adhere to the Extracellular Matrix of Inflamed Human Coronary Endothelium", J. Am. Coll. Cardiology, <u>27</u> :(92 Suppl 1):298A (1996).		
	23.	KENT et al., "Intimal hyperplasia--still here after all these years!", <i>Ann. Vasc. Surg.</i> , <u>18</u> (2):135-137 (2004).		
	24.	KIPSHIDZE et al., "Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model", <i>Catherization and Cardiovascular Interventions</i> , <u>54</u> :247-256 (2001).		
	25.	KIPSHIDZE et al., "Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model", <i>Catherization and Cardiovascular Interventions</i> , <u>64</u> :389-394 (2005).		
	26.	KIPSHIDZE et al., "Selective Systemic Delivery of Rapamycin by Using Perflurobutane Gas Microbubble Carrier Reduces Neointimal Formation in Stented Porcine Coronary Arteries", <i>The American Journal of Cardiology</i> , <u>92</u> (6 Suppl. 1) (2003).		
	27.	KLUGHERZ et al., "Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent", <i>Coron Artery Dis.</i> , <u>13</u> (3):183-8 (2002).		
	28.	KLUGHERZ et al., "Intramural Kinetics of Sirolimus Eluted from an Intracoronary Stent", <i>Circulation</i> , <u>102</u> (18 Supplement):ii:733, Abstract 3544 (2000).		
	29.	MARX, S.O., M.D. and MARKS, A.R., M.D., "Bench to bedside: the development of rapamycin and its application to stent restenosis", <i>Circulation</i> , <u>104</u> (8):852-855 (2001).		
	30.	MOSES et al., "Perspectives of drug-eluting stents: the next revolution", <i>Am J Cardiovasc Drugs</i> , <u>2</u> (3):163-72 (2002).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/668,988
				Confirmation Number	1777
				Filing Date	September 22, 2003
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1618
Examiner Name	Young, M.P.				
Attorney Docket No.	50450-8060				
Sheet	4	of	4		

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	31.	MOSES et al., "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery", <i>NEJM</i> , <u>349</u> :1315-1323 (2003).	
	32.	PORTER et al., "Non-Invasive Prevention of Lumen Area Narrowing Following Coronary Balloon Injury with Intravenous Antisense to the c-myc Protooncogene Bound to Perfluorocarbon Microbubbles," <i>Circulation</i> , <u>98</u> (17 Suppl.):I503 (1998).	
	33.	REGAR et al., "Stent development and local drug delivery", <i>Br Med Bull.</i> , <u>59</u> :227-48 (2001).	
	34.	SCHMELZLE, T. and HALL, M.N., "TOR, a central controller of cell growth" <i>Cell</i> , <u>103</u> :253-262 (2000).	
	35.	SUZUKI et al., "Stent-Bsed Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model", <i>Circulation</i> , <u>104</u> :1188-1193 (2001).	
	36.	TOPOL, E.J. and SERRUYS, P.W., "Frontiers in interventional cardiology", <i>Circulation</i> , <u>98</u> :1802-1820 (1998).	
	37.	WEISER-EVANS et al. "Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery smooth muscle cells after vascular injury", <i>Journal of Cellular Physiology</i> , <u>182</u> :12-23 (2000).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	